Every 8-K that C4 Therapeutics, Inc. (CCCC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CCCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCCC filings page.
C4 Therapeutics, Inc. reported second quarter 2026 results and provided clinical and corporate updates centered on its IKZF1/3 degrader cemsidomide. For the quarter ended June 30, 2026, revenue from collaboration agreements was $6.6 million, while research and development expense was $24.5 million and general and administrative expense was $8.6 million. Net loss was $23.6 million, or $0.18 per share.
Cash, cash equivalents and marketable securities totaled $300.4 million as of June 30, 2026, supported by a $20 million upfront payment from a new collaboration with Roche and $33.5 million in net proceeds raised through an at-the-market program. The company expects this cash to fund operations through the end of 2028.
Clinically, a Phase 2 multiple myeloma trial of cemsidomide plus dexamethasone is ongoing, with enrollment expected to complete in early 2027 and initial overall response rate data in the second half of 2027. A Phase 1b trial in combination with elranatamab is progressing, and another Phase 1b trial with standard-of-care multiple myeloma therapies is planned to initiate in the first half of 2027.
C4 Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting.
Stockholders gave a non-binding, advisory approval of named executive officer compensation and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the shares counted for the evergreen increase calculation.
C4 Therapeutics filed a report highlighting new clinical data and investor materials for its IKZF1/3 degrader cemsidomide in relapsed/refractory multiple myeloma. A fully enrolled Phase 1 trial of cemsidomide plus dexamethasone in 73 heavily pretreated patients showed a 53% overall response rate at the 100 µg once-daily recommended Phase 2 dose and 36% across all doses, with some responses deepening over time and minimal residual disease negativity in select patients. Median progression-free survival was 3.9 months and median duration of response was 7.9 months. Safety was characterized mainly by on‑target neutropenia, with 58% experiencing grade 3/4 neutropenia, few dose reductions and no discontinuations attributed to cemsidomide. The company is now enrolling a Phase 2 single‑arm study in fourth‑line and later multiple myeloma and a Phase 1b combination trial with the bispecific antibody elranatamab, while also outlining a broader strategy in oncology and inflammation/neuroinflammation indications.
C4 Therapeutics reported a change in its senior finance leadership roles. The company determined that Mark Mossler will no longer serve as Chief Accounting Officer, effective May 15, 2026, and stated that his departure does not involve any disagreement about financial reporting, operations, policies or practices.
Kendra R. Adams, currently Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the company’s principal accounting officer, also effective May 15, 2026. She will not receive additional compensation for this role, and no existing plans or arrangements involving her have been changed.
C4 Therapeutics reported first quarter 2026 results and highlighted progress in its protein degrader pipeline. Revenue was $6.2 million, down from $7.2 million a year earlier, mainly reflecting the conclusion and reprioritization of Merck collaborations. R&D expense declined to $24.6 million from $27.1 million, while G&A expense remained steady at $9.3 million.
Net loss narrowed slightly to $25.1 million, or $0.20 per share, compared with $26.3 million, or $0.37 per share, in the prior-year quarter. Cash, cash equivalents and marketable securities were $268.3 million as of March 31, 2026, and the company expects this to fund operations to the end of 2028.
The company advanced cemsidomide in multiple myeloma with Phase 2 and Phase 1b trials enrolling and plans an additional Phase 1b combination trial in 2027. It also expanded its long-term partnership with Roche through a new degrader‑antibody conjugate collaboration, including a $20 million upfront payment, and decided not to advance CFT8919 in non-small cell lung cancer outside Greater China.
C4 Therapeutics, Inc. reported that its Board of Directors approved an immediate amendment to the company’s second amended and restated by-laws on April 9, 2026. The change designates the U.S. District Courts for the District of Massachusetts and the District of Delaware as the exclusive forums for resolving federal securities law claims, unless the company agrees in writing to another forum.
The amendment covers actions arising under the Securities Act of 1933, the Securities Exchange Act of 1934, and related rules and regulations. The Board adopted this forum selection provision in response to recent amendments to Delaware corporate law. The full text of the by-laws amendment is filed as an exhibit.
C4 Therapeutics, Inc. entered into a major research collaboration and license agreement with Roche to discover, develop and commercialize degrader‑antibody conjugates (DACs) for oncology. C4T grants Roche a worldwide, exclusive license for DACs against two undisclosed cancer targets, while Roche funds all development, regulatory, manufacturing and commercialization activities.
C4T will receive a $20.0 million upfront cash payment and is eligible for over $1.0 billion in development, regulatory and commercial milestone payments, plus tiered royalties ranging from mid‑single digit to low‑double digit percent on net sales. Roche also holds an option, for an additional fee, to add a third oncology target with its own milestones and royalties. The agreement can be terminated for customary reasons, and Roche may also terminate for convenience with 90 days’ notice.
C4 Therapeutics reported fourth quarter and full-year 2025 results and outlined progress across its pipeline. Total revenue was $11.0 million for Q4 and $35.9 million for 2025, roughly flat year over year, while operating expenses declined modestly.
Full-year R&D was $104.2 million and G&A was $36.2 million, contributing to a net loss of $105.0 million, or $1.27 per share. Cash, cash equivalents and marketable securities were $297.1 million as of December 31, 2025, and the company expects this to fund its operating plan to the end of 2028. Strategically, cemsidomide advanced into a Phase 2 trial in later-line multiple myeloma, a Phase 1b combination study with elranatamab is expected to start in Q2 2026, C4T earned a $2 million milestone from Biogen for BTK degrader BIIB145, and it raised $125 million in an October 2025 equity offering.
C4 Therapeutics, Inc. filed a Form 8-K to furnish information about a new corporate update. On January 14, 2026, the company issued a press release that outlines its milestones through 2028 and highlights recent achievements, and has attached this press release as Exhibit 99.1.
The disclosure is made under Item 7.01 (Regulation FD Disclosure), which means the information in the press release and Item 7.01 is being furnished rather than filed and is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities law filings. The report is signed on behalf of the company by its Chief Financial Officer and Treasurer, Kendra R. Adams.
C4 Therapeutics, Inc. furnished a press release announcing its financial results and business highlights for the quarter ended September 30, 2025.
The press release, dated November 6, 2025, is included as Exhibit 99.1 to this Form 8-K and is treated as furnished rather than filed under the Exchange Act.
C4 Therapeutics announced an underwritten equity offering consisting of 21,895,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 28,713,500 shares. Each share or pre-funded warrant was sold together with accompanying Class A and Class B warrants, at a combined price of $2.47 per share package and $2.4699 per pre-funded package. The company expects approximately $117.0 million in net proceeds, extending its cash runway to the end of 2028. If all warrants are cash exercised in full, aggregate net proceeds are expected to be $341.7 million. Closing is expected on October 17, 2025, subject to customary conditions.
The pre-funded warrants have a $0.0001 exercise price and do not expire. Class A and Class B warrants each have an initial exercise price of $2.22 per share and are exercisable immediately. Class A warrants expire on the earlier of 30 days after public release of nine-month median follow-up data from any expansion cohort in the planned Phase 1b study of cemsidomide with elranatamab or the fifth anniversary; Class B warrants expire on the fifth anniversary and may be mandatorily exercised after six months if the stock closes above $6.66 for ten consecutive trading days. Warrant exercises are subject to a Beneficial Ownership Limitation of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice.
C4 Therapeutics, Inc. (CCCC) announced two updates. The company posted a presentation with data from its Phase 1 trial of cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma, available on its investor relations site and filed as Exhibit 99.1.
The company also ended its current ATM prospectus. Effective October 16, 2025, the sales agreement prospectus dated November 13, 2024 was terminated. The underlying Sales Agreement with TD Securities (USA) LLC (TD Cowen) remains in effect, and no further common stock sales will be made under that prospectus unless a new prospectus supplement or a new registration statement with sales agreement prospectus is filed. As of June 30, 2025, the company had sold 3,769,483 shares under the Sales Agreement for gross proceeds of approximately $9.6 million before commissions.
C4 Therapeutics, Inc. announced on October 1, 2025 that it entered a clinical trial collaboration and supply agreement with Pfizer. Under the agreement, Pfizer will supply elranatamab (ELREXFIO®), a BCMAxCD3 bispecific antibody, at no cost for C4's upcoming Phase 1b trial testing the safety and tolerability of cemsidomide plus dexamethasone in combination with elranatamab for patients receiving second-line or later therapy for multiple myeloma. C4 will sponsor and run the trial while Pfizer will receive access to trial data. The company furnished a press release as Exhibit 99.1 to the current report.
C4 Therapeutics, Inc. (CCCC) reported that it issued a press release and presented clinical data from its Phase 1 trial of cemsidomide plus dexamethasone for relapsed/refractory multiple myeloma at the International Myeloma Society (IMS) Meeting in an oral presentation on September 20, 2025. The company furnished the press release as Exhibit 99.1 and posted the presentation slides on its investor relations site, filing those slides as Exhibit 99.2 to this Current Report on Form 8-K. The filing states these materials are "furnished" (not "filed") and does not include financial results or detailed trial outcomes within the Form text. The company also notes the furnishing does not constitute an admission as to materiality.